S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04. (23rd June 2022) - Touzeau, C.; Perrrot, A.; Hulin, C.; Manier, S.; Macro, M.; Chretien, M.-L.; Karlin, L.; Decaux, O.; Jacquet, C.; Tiab, M.; Leleu, X.; Planchce, L.; et al.